$1.30 billion in sales expected for Encompass Health Co. (NYSE:EHC) this quarter
Analysts expect Encompass Health Co. (NYSE:EHC) to report revenue of $1.30 billion in the current quarter, reports Zacks Investment Research. Five analysts have made earnings estimates for Encompass Health, with the highest sales estimate at $1.31 billion and the lowest estimate at $1.30 billion. Encompass Health reported sales of $1.21 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 7.4%. The company is expected to release its next earnings report after the market closes on Tuesday, February 1.
On average, analysts expect Encompass Health to have annual sales of $5.11 billion in the current fiscal year, with estimates ranging from $5.10 billion to $5.12 billion. For the next fiscal year, analysts expect the company to record sales of $5.49 billion, with estimates ranging from $5.42 billion to $5.64 billion. Zacks Investment Research sales averages are an average average based on a survey of research companies that track Encompass Health.
Encompass Health (NYSE:EHC) last released its results on Tuesday, February 1. The company reported earnings per share (EPS) of $0.97 for the quarter, missing the consensus estimate of $1.05 per ($0.08). Encompass Health had a net margin of 8.10% and a return on equity of 19.87%. The company posted revenue of $11.32 billion in the quarter, compared to analysts’ estimates of $1.31 billion. In the same quarter a year earlier, the company posted EPS of $0.93. The company’s quarterly revenue increased 832.0% year over year.
Several analysts have recently commented on the stock. Raymond James cut his price target on Encompass Health shares from $107.00 to $90.00 and set a “Strong Buy” rating for the company in a Tuesday, November 2 research report. Zacks Investment Research downgraded shares of Encompass Health from a “buy” rating to a “hold” rating and set a price target of $67.00 for the company. in a research report on Tuesday, November 2. Truist Financial cut its price target on Encompass Health shares from $100.00 to $88.00 and set a “buy” rating for the company in a Wednesday, October 13 research report. BMO Capital Markets cut its price target on Encompass Health shares from $102.00 to $75.00 and set an “outperform” rating for the company in a Monday, November 1 research report. Finally, TheStreet downgraded shares of Encompass Health from a “b-” rating to a “c+” rating in a Monday, November 15 research report. One equity research analyst gave the stock a hold rating, seven gave the company a buy rating and one gave the company a strong buy rating. According to MarketBeat, Encompass Health currently has a consensus rating of “Buy” and a consensus target price of $86.67.
EHC stock opened at $61.46 on Wednesday. The company has a fifty-day simple moving average of $64.02. Encompass Health has a 12 month minimum of $56.31 and a 12 month maximum of $89.68. The stock has a market capitalization of $6.11 billion, a P/E ratio of 15.14, a price-to-earnings growth ratio of 0.73 and a beta of 1.02. The company has a debt ratio of 1.39, a quick ratio of 1.15 and a current ratio of 1.15.
Institutional investors and hedge funds have recently changed their positions in the company. The Public Employees Retirement System of Ohio increased its holdings of Encompass Health shares by 8.0% in the second quarter. The Ohio Public Employees Retirement System now owns 60,037 shares of the company valued at $4,685,000 after purchasing an additional 4,459 shares last quarter. The New York State Teachers Retirement System increased its stake in Encompass Health by 14.5% in Q3. The New York State Teachers’ Retirement System now owns 49,152 shares of the company valued at $3,688,000 after acquiring 6,228 additional shares in the last quarter. Metropolitan Life Insurance Co NY increased its stake in Encompass Health by 107,325.0% in Q2. Metropolitan Life Insurance Co NY now owns 21,485 shares of the company valued at $1,676,000 after acquiring an additional 21,465 shares in the last quarter. Orchard Capital Management LLC increased its stake in Encompass Health by 14.9% in Q2. Orchard Capital Managment LLC now owns 108,266 shares of the company valued at $8,448,000 after acquiring an additional 14,024 shares in the last quarter. Finally, Keeley Teton Advisors LLC increased its stake in Encompass Health by 8.7% in the third quarter. Keeley Teton Advisors LLC now owns 27,226 shares of the company valued at $2,043,000 after acquiring 2,186 additional shares in the last quarter. Institutional investors and hedge funds own 90.21% of the company’s shares.
About Encompass Health
Encompass Health Corp. engages in the provision of post-acute healthcare services. It operates through Inpatient Rehabilitation and Home Health and Hospice segments. The Inpatient Rehabilitation segment operates inpatient rehabilitation hospitals that provide rehabilitative treatment and care to patients recovering from stroke and other neurological disorders, heart and lung disorders, brain injuries and spinal cord injuries, complex orthopedic disorders and amputations.
See also: What is a death cross?
Get a free copy of Zacks’ research report on Encompass Health (EHC)
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Encompass Health right now?
Before you consider Encompass Health, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Encompass Health wasn’t on the list.
Although Encompass Health currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here